Humacyte (NASDAQ:HUMA) vs. Genetic Technologies (NASDAQ:GENE) Head-To-Head Comparison

Genetic Technologies (NASDAQ:GENE) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Insider and Institutional Ownership

0.6% of Genetic Technologies shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 6.5% of Genetic Technologies shares are held by company insiders. Comparatively, 11.2% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Genetic Technologies and Humacyte, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genetic Technologies	0	0	0	0	0.00
Humacyte	0	1	6	1	3.00

Humacyte has a consensus target price of $13.71, indicating a potential upside of 716.33%. Given Humacyte’s stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than Genetic Technologies.

Valuation and Earnings

This table compares Genetic Technologies and Humacyte”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genetic Technologies	$7.66 million	0.44	-$7.88 million	N/A	N/A
Humacyte	$1.57 million	165.99	-$110.78 million	($1.26)	-1.33

Genetic Technologies has higher revenue and earnings than Humacyte.

Risk and Volatility

Genetic Technologies has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Profitability

This table compares Genetic Technologies and Humacyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genetic Technologies	N/A	N/A	N/A
Humacyte	N/A	-942.81%	-93.82%

Summary

Humacyte beats Genetic Technologies on 8 of the 12 factors compared between the two stocks.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

About Humacyte

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.